ITGAV and neoplasm: Given the aggressive growth and enhanced metastasis associated with patient cSCC relapses [3, 4] and the scarcity of prognostic biomarkers, we tested the plasticity marker ITGAV as a prognostic biomarker of tumor relapse in cSCC patient samples.